EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Active surveillance for intermediate‐risk prostate cancer: a systematic review and pooled analysis

Alessandro Uleri, Ludovica Cella iD, Thibaut Long-Depaquit iD, Federica Sordelli iD, Alba Farré, Victor Caballero, Josep Comet, Pawel Rajwa, Romain Diamand, Bertrand Tombal iD, Morgan Roupret, Veeru Kasivisvanathan und 3 weitere

BJU International · 2026-11 · 138 (5) · 759-768

DOI: 10.1111/bju.70388 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift BJU International, online erschienen am 26.07.2026. Verfasst von Alessandro Uleri und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Josep Trueta University Hospital, Girona, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Watchful Waiting. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Active surveillance (AS) is the preferred management for individuals with low‐risk prostate cancer (PCa), but its role in intermediate‐risk (IR) disease remains underreported. Given growing interest and published data, we performed an updated systematic review and meta‐analysis to evaluate AS outcomes in selected patients with Gleason Grade Group (GG) 1–2 IR PCa.

Methods

A systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines (PROSPERO CRD420251138532). PubMed/MEDLINE, Embase, and Web of Science databases were searched for studies published up to September 2025 reporting outcomes of AS in IR PCa. Primary outcomes were AS discontinuation‐free survival and GG ≥3 upgrade‐free survival.

Results

In total, 18 studies, including 3783 selected patients with IR PCa, were analyzed. Pooled AS discontinuation‐free survival rates were 70% (95% confidence interval [CI] 62–78) at 3 years, 63% (95% CI 58–68) at 5 years, and 53% (95% CI 38–67) at 10 years. In analyses restricted to GG 2 cohorts, corresponding pooled estimates were 72% at 3 years, 56% at 5 years, and 40% at 10 years. GG ≥3 upgrade‐free survival was 84% (95% CI 76–92) at 3 years and 78% (95% CI 65–91) at 5 years in all cohorts and 92% (95% CI 86–98) and 87% (95% CI 78–95) at 3 and 5 years in cohorts screened using multiparametric magnetic resonance imaging. No significant difference in AS discontinuation was observed between biopsy GG 1 and 2 (hazard ratio 1.08; 95% CI 0.86–1.35). Limitations include moderate risk of bias and heterogeneity across AS protocols.

Conclusions

Although long‐term data are lacking, particularly regarding robust oncological outcomes, growing evidence suggests that AS appears oncologically safe in well‐selected patients. Magnetic resonance imaging will play a key role in the appropriate selection and follow‐up of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsWatchful WaitingHumansMaleNeoplasm GradingRisk Assessment

Stichwörter der Autor:innen

ISUP 2MRIactive surveillanceintermediate riskprostate cancer

Autor:innen und Institutionen

  • Department of Urology, Josep Trueta University Hospital, Girona, Spain.
  • Department of Urology, Humanitas Clinical and Research Institute IRCCS, Milan, Italy.
  • Department of Urology, APHM, North Academic Hospital, Marseille, France.
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Department of Urology, Medical University of Silesia, Zabrze, Poland.
  • Department of Urology, Jules Bordet Institute, Hôpital Universitaire de Bruxelles, Brussels, Belgium.

ORCID-Profile: Ludovica Cella, Thibaut Long-Depaquit, Federica Sordelli, Bertrand Tombal, Guillaume Ploussard

Zitieren

APA

Uleri, A., Cella, L., Long-Depaquit, T., Sordelli, F., Farré, A., Caballero, V., Comet, J., Rajwa, P., Diamand, R., Tombal, B., Roupret, M., Kasivisvanathan, V., Leapman, M. S., Ploussard, G., & Baboudjian, M. (2026). Active surveillance for intermediate‐risk prostate cancer: a systematic review and pooled analysis. BJU International, 138(5), 759-768. https://doi.org/10.1111/bju.70388

Vancouver

Uleri A, Cella L, Long-Depaquit T, Sordelli F, Farré A, Caballero V, et al. Active surveillance for intermediate‐risk prostate cancer: a systematic review and pooled analysis. BJU International. 2026;138(5):759-768. doi:10.1111/bju.70388

BibTeX
@article{Uleri2026,
  author = {Uleri, Alessandro and Cella, Ludovica and Long-Depaquit, Thibaut and Sordelli, Federica and Farré, Alba and Caballero, Victor and Comet, Josep and Rajwa, Pawel and Diamand, Romain and Tombal, Bertrand and Roupret, Morgan and Kasivisvanathan, Veeru and Leapman, Michael S and Ploussard, Guillaume and Baboudjian, Michael},
  title = {Active surveillance for intermediate‐risk prostate cancer: a systematic review and pooled analysis},
  journal = {BJU International},
  year = {2026},
  volume = {138},
  number = {5},
  pages = {759--768},
  doi = {10.1111/bju.70388}
}
Kostenlos starten →